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Summary
oral anaplastic lymphoma kinase (aLK) tyrosine kinase 
inhibitors (tKI) have shown significant benefit in the 
management of aLK-rearranged non-small cell lung 
cancer (NsCLC). However, almost all patients will 
experience disease progression after front-line aLK-
tKIs such as crizotinib. treatment with third generation 
aLK-tKI lorlatinib can have a significant clinical impact 
following disease progression, even in patients with 
a very poor performance status. Here, we review 
two clinical cases with metastatic aLK-rearranged 
NsCLC who had pulmonary disease control with first-
generation aLK inhibitor. However, disease progressed 
rapidly in the central nervous system with severe 
neurological symptoms. treatment with lorlatinib, a 
third-generation aLK-tKI, led to a rapid radiological 
and clinical cerebral response in both patients. 
Lorlatinib can overcome aLK resistance to crizotinib, 
and the presented cases suggest a potential role for 
lorlatinib in patients with rapidly progressive cerebral 
and leptomeningeal metastases.
BaCkground
A small subset (3%–13%) of patients with non-small 
cell lung cancer (NSCLC) develop rearrangements 
in the anaplastic lymphoma kinase(ALK) gene. Over 
the last few years, small molecule tyrosine kinase 
inhibitors (TKIs) have shown significant benefit 
in the management of ALK-rearranged NSCLC.1 
Crizotinib, a first-generation ALK inhibitor has 
a significant activity in ALK-rearranged NSCLC. 
Progression-free survival (PFS) for crizotinib 
group was 10.9 months and for platinum-based 
chemotherapy group was 7.0 months. The overall 
response rate (ORR) was 74% (95% CI 67% to 
81%) for crizotinib versus 45% (95% CI 37% to 
53%) for chemotherapy.1 
However, most patients with NSCLC experience 
disease progression of the central nervous system 
during treatment with crizotinib in first-line setting. 
Treatment with more potent and selective next-gen-
eration ALK-TKIs demonstrated outstanding 
activity in both crizotinib-naïve and crizotinib-resis-
tant ALK-rearranged NSCLC, with superior pene-
tration of the blood–brain barrier (BBB).1
Ceritinib, brigatinib and alectinib are a selective 
second-generation ALK-TKIs and are more potent 
than crizotinib against native ALK protein and are 
able to inhibit gatekeeper mutations.1
Objective response rates for these ALK inhibitors 
in postcrizotinib setting seem similar across most 
trials.
The ASCEND -1 trial showed an intracranial 
ORR of 56% (95% CI 45% to 67%) for ceritinib 
in patients who progressed under crizotinib, and a 
progression free survival of 6.9 months (95% CI 5.6 
to 9.5).2
According to a phase I/II trial, the ORR of briga-
tinib was 71% (95% CI 59% to 82%) in patients 
pretreated with crizotinib, with an overall median 
PFS of 13.4 months.3
Just recently as presented at American Society of 
Clinical Oncology 2018, the ALEX trial, comparing 
alectinib with crizotinib in treatment-naive ALK-re-
arranged NSCLC, showed a PFS of 34.8 months 
(95% CI 17.7 to not estimable) for alectinib 
compared with crizotinib 10.4 months (95% CI 9.1 
to 12.9), making alectinib now a drug of choice for 
the front-line therapy of ALK-rearranged NSCLC.4
Currently, third-generation TKIs are being devel-
oped and assessed. Lorlatinib is a third-generation 
ALK/ROS1 TKI for patients who are refractory to 
both crizotinib and ceritinib.5 The physiochemical 
properties of lorlatinib were specifically created to 
have a high potency in inhibiting ALK phosphoryla-
tion and to maximise central nervous system (CNS) 
availability by controlling molecular structure.
The selectivity of lorlatinib is enhanced by 
targeting of a specific residue in the ALK tyro-
sine kinase domain—leucine at position 1198 
(L1198)—which is detected in only approximately 
25% of kinases.5 Lorlatinib is ∼10-fold more potent 
against wild-type EML4–ALK and ∼40-fold more 
potent against EML4–ALK L1196M as compared 
with crizotinib.6 Lorlatinib was designed to be a 
low-efflux substrate from cell lines overexpressing 
P-glycoprotein to increase its potential CNS pene-
tration.6 The cerebral response rate varies between 
50% and 80%.5
Lorlatinib was recently Food and Drug Admin-
istration approved based on a non-randomised, 
dose-ranging and activity-estimating, multicohort, 
multicentre phase I/II study, evaluating lorlatinib 
for the treatment of patients with ALK-positive 
metastatic NSCLC, who were previously treated 
with one or more ALK-TKIs. A total of 215 patients 
with ALK-positive metastatic NSCLC were enrolled 
across various subgroups based on prior treatment. 
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42% to 55%), and importantly, 57% had previous treatment 
with more than one ALK-TKI. In the trial, 69% of patients had 
a history of brain metastases, and intracranial ORR was 60% 
(95% CI 49% to 70%). Responses were rapid. The median time 
to first tumour response was just 1–4 months. Lorlatinib even 
maintains its clinical activity regardless of number of previous 
administrated TKIs.5–7
Here, we describe two cases with metastatic ALK-rearranged 
NSCLC who had pulmonary disease control with first-genera-
tion ALK inhibitor. However, treatment with crizotinib had no 
effect on the CNS metastases. Treatment with lorlatinib led to a 




A 48-year-old woman was diagnosed with stage IV NSCLC 
of the left lower lobe. Molecular analysis on a cervical lymph 
node revealed an ALK rearrangement, confirmed with fluo-
rescent in situ hybridisation and immunohistochemistry. Treat-
ment with crizotinib 250 mg two times per day was initiated. 
After 1 month, a follow-up CT scan showed regression of the 
lung tumour and extrapulmonary metastases. However, tumour 
markers increased, suggesting incomplete disease control. Since 
the patient had a clear clinical benefit, treatment with crizotinib 
was continued.
Case 2
A 54-year-old man with ALK-rearranged stage IV NSCLC of 
the right lower lobe started with crizotinib. After 4 months, a 
CT scan showed radiological partial intrathoracic response.
ouTCome and follow-up
Case 1
An MRI of the brain was planned despite the fact that she had no 
symptoms suggesting brain involvement. The MRI of the brain 
showed multiple metastases on the right parietal and occipital 
lobe, without evident hydrocephalus (figure 1). At the same 
time, a thoracoabdominal CT scan showed further regression 
of the lung tumour and the extrapulmonary metastases. Ceri-
tinib was the only available second-line drug and treatment was 
started at a dose of 750 mg/day. After 11 days of treatment, the 
patient, however, developed a progressive paresis of the right 
arm and reduced consciousness, with a Glascow Coma Scale 
of 13. The new neurological symptoms were based on a new 
obstructive hydrocephalus although high doses of dexametha-
sone (16 mg/day). We placed a ventriculoperitoneal drain to 
reduce the intracranial pressure. However, several days after 
start of ceritinib, the patient’s condition continued to deterio-
rate. At that time, the patient became comatose. Ceritinib was 
switched to lorlatinib 100 mg/day through a nasogastric tube. 
Within 2 days, the patient showed neurological improvement 
with a gradual decline of tumour markers (figure 2). One month 
after the start of lorlatinib, the patient had a complete recovery 
of consciousness and a clear improvement of the paresis of the 
right arm with only minimal neurological sequelae. After 1 year, 
the patient still has minimal neurological symptoms and a MRI 
scan of the brain shows no sign of metastases. The intrathoracic 
disease still continued to decrease in size.
Case 2
After more than 1 year, the disease slowly progressed, therefore 
crizotinib was switched to brigatinib.
Unfortunately, after 2 months of treatment with brigatinib, 
the patient developed headaches, nausea, vomiting and paraes-
thesia of the right hand. An MRI scan showed multiple new 
cerebral and leptomeningeal metastases (figure 3), while intra-
thoracic disease was still stable. Lorlatinib was started 100 mg/
day, and the patient recovered fully within days. However, the 
tumour markers did not decline at a same pace as seen in case 1.
After 1 year the patient has no symptoms related to his tumour. 
The MRI scan shows regression of the cerebral and leptome-
ningeal metastases, whereas the intrathoracic disease slightly 
figure 1 Resolution of intracranial metastases of patient in case 1. 
MRI scans of (A) and (C) show multiple intracranial metastases during 
crizotinib use, whereas, MRI scans of (B) and (D) show regression of the 
intracranial metastases after 1 week therapy with lorlatinib.
figure 2 Tumour markers activity after starting ceritinib and lorlatinib. 
At baseline, (day 0) the patient in case 1 was using ceritinib. When 
the neurological symptoms progressed, lorlatinib was started at day 
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progressed, however without symptoms, and therefore lorlatinib 
is being continued at the time of reporting.
diSCuSSion
In these two cases, a second-generation ALK-TKI appeared to 
be less efficacious than lorlatinib in targeting the brain metas-
tases as both patients showed neurological deterioration during 
treatment with a second-generation ALK-TKI and a rapid clin-
ical and radiological improvement after switch to lorlatinib. 
There are several reasons for the development of intracranial 
disease progression in patients treated with a second-generation 
ALK-TKI.
First, different mechanisms of acquired resistance to first and 
second-generation TKIs, including secondary ALK mutations, 
ALK fusion gene amplification and activation of alternative 
signalling pathways have been identified.5
Lorlatinib is 30-fold more potent than crizotinib in suppressing 
ALK-dependent signalling and inhibitory cell growth and 
inducing apoptosis, therefore, making it the most potent 
inhibitor against all clinical relevant crizotinib, ceritinib and 
alectinib-resistant ALK mutation, especially against G1202R, 
which is the most common cause of resistance against first and 
second-generation TKIs.7–9
In these cases, it is not known whether a mutation had devel-
oped resulting in an acquired resistance to crizotinib, brigatinib 
and ceritinib. Due to the rapid course of the disease and site 
of progression, a biopsy for molecular analysis could not be 
obtained.
A second reason for developing intracranial disease progression 
is the disability to cross the BBB. It is known that the first-gen-
eration oral TKIs, such as crizotinib, have a low penetration of 
the BBB, while the majority of second and third-generation ALK 
inhibitors efficiently penetrates the BBB, reaching high concen-
trations in the cerebral spinal fluid. Actually, the ratio of the CNS 
to serum concentration of crizotinib seems to be in the range 
of 0.0006–0.001, as established by individual case reports.1 
Whereas, in vivo studies demonstrated that CSF concentra-
tions of lorlatinib achieved 75% of unbound plasma concentra-
tions. In addition, BBB penetration by lorlatinib was confirmed 
by Collier et al using carbon11-labelled and fluorine18-labelled 
lorlatinib and initial positron emission tomography imaging in a 
non-human primate model.5
Zou et al demonstrated that a more potent ALK inhibitor 
with 1.5-fold greater potency than lorlatinib but with a low 
CNS availability (6%) failed to sustain tumour growth inhibition 
in the same intracranial tumour model, suggesting penetration 
into the brain metastasis plays a major role in the activity of 
lorlatinib.9
Overall, these results suggest that lorlatinib can effectively 
cross the BBB to induce significant and durable CNS responses.7 8
In our first case, ceritinib was used briefly, therefore the 
actual effect of ceritinib on the brain metastases remains largely 
unknown, but a treatment switch was thought to be adamant.
However, the clinical deterioration together with the serum 
tumour marker pattern suggested progression. Whereas, the 
use of ventriculoperitoneal drain showed no effect on patient’s 
clinic, possibly due the already existing hydrocephalus. Measure-
ment of carcinoembryonic antigen (CEA) over time was shown 
to be useful as a predictive marker for the disease course. Serum 
CEA levels might reflect the extent of disease and therapeutic 
response in some ALK-rearranged NSCLC patients.
In case 2, disease progressed despite using brigatinib for 
2 months.
The subsequent rapid decline of the tumour markers in case 1 
and swift clinical improvement in both patients indicate a rapid 
antitumour activity of lorlatinib in the brain. This was confirmed 
both clinically and radiologically in both cases. The good cere-
bral response on lorlatinib in our patients suggests that lorla-
tinib can be an alternative to brain radiotherapy in patients with 
cerebral progression during treatment with a second-generation 
ALK-TKI.
learning points
 ► Lorlatinib seems to be able to overcome cerebral anaplastic 
lymphoma kinase (ALK) resistance to first or second-
generation ALK inhibitor such as crizotinib, ceritinib and 
brigatinib.
 ► Lorlatinib seems to be able to penetrate the blood–brain 
barrier and shows a remarkable rapid cerebral response 
in patients with cerebral progression and a very poor 
performance status despite treatment with second-generation 
ALK tyrosine kinase inhibitor (TKI).
 ► Treatment with lorlatinib can therefore be considered as 
an alternative to brain radiotherapy in patients with rapid 
neurological deterioration during treatment with a second-
generation ALK-TKI.
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figure 3 Resolution of intracranial and leptomeningeal metastases 
of patient in case 2. MRI scans of (A) and (C) show multiple intracranial 
and leptomeningeal metastases during brigatinib use, whereas 
MRI scans of (B) and (D) show regression of the intracranial and 
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